<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Application of the screening method to monitor influenza vaccine effectiveness among the elderly in Germany</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Cornelius</forename><surname>Remschmidt</surname></persName>
							<email>remschmidtc@rki.de</email>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Immunization Unit</orgName>
								<orgName type="institution" key="instit2">Robert Koch Institute</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Immunization Unit</orgName>
								<orgName type="institution" key="instit2">Robert Koch Institute</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thorsten</forename><surname>Rieck</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Immunization Unit</orgName>
								<orgName type="institution" key="instit2">Robert Koch Institute</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Immunization Unit</orgName>
								<orgName type="institution" key="instit2">Robert Koch Institute</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution">Charité -University Medicine Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Birte</forename><surname>Bödeker</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Immunization Unit</orgName>
								<orgName type="institution" key="instit2">Robert Koch Institute</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Immunization Unit</orgName>
								<orgName type="institution" key="instit2">Robert Koch Institute</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ole</forename><surname>Wichmann</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Immunization Unit</orgName>
								<orgName type="institution" key="instit2">Robert Koch Institute</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Immunization Unit</orgName>
								<orgName type="institution" key="instit2">Robert Koch Institute</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Application of the screening method to monitor influenza vaccine effectiveness among the elderly in Germany</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">CC3B952A70A5D93F5471DC0F7FF39D63</idno>
					<idno type="DOI">10.1186/s12879-015-0882-3</idno>
					<note type="submission">Received: 17 July 2014 Accepted: 12 March 2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:32+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Influenza</term>
					<term>Vaccine effectiveness</term>
					<term>Screening method</term>
					<term>Elderly</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: Elderly people are at increased risk for severe influenza illness and constitute therefore a major target-group for seasonal influenza vaccination in most industrialized countries.</s><s>The aim of this study was to estimate influenza vaccine effectiveness (VE) among individuals aged 60+ years over three seasons and to assess if the screening method is a suitable tool to monitor influenza VE in this particular target-group in Germany.</s></p><p><s>Methods: We identified laboratory-confirmed influenza cases aged 60+ years through the national communicable disease reporting system for seasons 2010/11, 2011/12 and 2012/13.</s><s>Vaccination coverage (VC) data were retrieved from a database of health insurance claims representing ~85% of the total German population.</s><s>We applied the screening method to calculate influenza subtype-specific VE and compared our results with VE estimates from other observational studies in Europe.</s></p><p><s>Results: In total, 7,156 laboratory-confirmed influenza cases were included.</s><s>VE against all influenza types ranged between 49% (95% confidence interval [CI]: 39-56) in 2011/12 and 80% (95% CI: 76-83%) in 2010/11.</s><s>In 2010/11 subtype-specific VE against influenza A(H1N1)pdm and B was 76% and 84%, respectively.</s><s>In the following seasons, VE against influenza A(H1N1)pdm, A(H3N2) and B was 87%, -9% , 74% (2011/12), and 74%, 39%, 73% (2012/13).</s><s>VE was higher among hospitalized compared to non-hospitalized influenza A cases.</s><s>Seventeen observational studies from Europe reporting subtype-specific VE among the elderly were identified for the respective seasons (all applying the test-negative design) and showed comparable subtype-specific VE estimates.</s></p><p><s>Conclusions: According to our study, influenza vaccination provided moderate protection against laboratory-confirmed influenza A(H1N1)pdm and B in individuals aged 60+ but no or only little protection against A(H3N2).</s><s>Higher VE among hospitalized cases might indicate higher protection against severe influenza disease.</s><s>Based on the available data, the screening method allowed us to assess subtype-specific VE in hospitalized and non-hospitalized elderly persons.</s><s>Since controlling for several important confounders was not possible, the applied method only provided crude VE estimates.</s><s>However, given the precise VC-data and the large number of cases, the screening method provided results being in line with VE estimates from other observational studies in Europe that applied a different study design.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background</head><p><s>Elderly people are at increased risk for severe influenza disease or influenza-associated complications <ref type="bibr" target="#b0">[1]</ref>.</s><s>Therefore, the World Health Organization (WHO) and National Immunization Technical Advisory Groups (NITAGs) in most industrialized countries recommend seasonal influenza vaccination for this particular at-risk group <ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b5">[5]</ref>.</s><s>The European Union aims to achieve a vaccination coverage of &gt;75% in this age-group to reduce influenzaassociated morbidity and mortality <ref type="bibr" target="#b6">[6]</ref>.</s><s>However, due to progressive deterioration in both innate and adaptive immune function, aging is associated with a reduced immune response to influenza vaccines <ref type="bibr" target="#b7">[7]</ref>.</s><s>Although it seems plausible that this also translates into reduced vaccine effectiveness (VE) in this age-group, there are still conflicting conclusions drawn by authors in respect to influenza VE among the elderly <ref type="bibr" target="#b8">[8]</ref>.</s><s>While some authors concluded that evidence on influenza VE in this age-group is poor <ref type="bibr" target="#b8">[8]</ref> or even lacking <ref type="bibr" target="#b9">[9]</ref>, others foundbased on results from post-marketing observational studiesevidence for a substantial reduction in influenza-related morbidity and mortality among the elderly <ref type="bibr" target="#b10">[10]</ref>.</s></p><p><s>To guide national immunization strategies and research into the development of improved influenza vaccines, annual estimates of influenza VE in vaccination target-groups are important <ref type="bibr" target="#b11">[11]</ref>.</s><s>In fact, suboptimal effectiveness of seasonal influenza vaccines has recently led researchers and policy makers to advocate for better vaccines <ref type="bibr" target="#b9">[9,</ref><ref type="bibr" target="#b12">12]</ref>.</s><s>Since VE varies not only by characteristics of the vaccinees (e.g., age or underlying medical conditions), but also by influenza season and subtype, many countries have established annual assessments of influenza VE.</s><s>An increasingly applied method to assess influenza VE is the test-negative design (TND) <ref type="bibr" target="#b13">[13]</ref><ref type="bibr" target="#b14">[14]</ref><ref type="bibr" target="#b15">[15]</ref><ref type="bibr" target="#b16">[16]</ref><ref type="bibr" target="#b17">[17]</ref>. Patients with medically attended acute respiratory illness (ARI) constitute the study population, and participants are considered as cases if they are tested positive for influenza and as controls if tested negative in a specific time-period after symptom onset <ref type="bibr" target="#b18">[18,</ref><ref type="bibr" target="#b19">19]</ref>.</s><s>In addition to the TND, the screening method has been used to estimate seasonal and pandemic VE in various settings <ref type="bibr" target="#b20">[20]</ref><ref type="bibr" target="#b21">[21]</ref><ref type="bibr" target="#b22">[22]</ref><ref type="bibr" target="#b23">[23]</ref><ref type="bibr" target="#b24">[24]</ref>.</s><s>This method estimates VE by comparing vaccination coverage (VC) in influenza-positive cases with VC in the population where the cases derived from (e.g., the same age-group) <ref type="bibr" target="#b25">[25]</ref>.</s><s>If representative data on influenza cases and influenza VC are available, the screening method provides an inexpensive and ready-to-use method that can be useful in providing early VE estimates <ref type="bibr" target="#b26">[26]</ref> or in identifying changes in VE over time when conducted repeatedly <ref type="bibr" target="#b14">[14,</ref><ref type="bibr" target="#b20">20]</ref>.</s><s>However, compared to TND the screening method seems more prone to selection bias, and controlling for important confounders, such as comorbidities, might not be possible due to lack of availability of these data <ref type="bibr" target="#b25">[25]</ref>.</s><s>Nonetheless, when applying stratified analyses or limiting the analysis to a more homogeneous population (such as elderly persons) the risk of bias can be reduced.</s></p><p><s>With this study we aimed to (i) estimate VE against laboratory-confirmed influenza for the seasons 2010/11-2012/13 among persons aged 60+ years, (ii) compare VE in preventing hospitalized and non-hospitalized influenza, and (iii) assess if the screening methods is a suitable tool for the monitoring of influenza VE among the elderly in Germany.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Database for determining population vaccination coverage</head><p><s>The source for seasonal influenza VC was the central database of health insurance claims of the Associations of Statutory Health Insurance Physicians (ASHIPs) in Germany.</s><s>ASHIPs administrative regions are identical to the geographic regions of the 16 federal states, except for one federal state that is divided into two ASHIP regions.</s><s>ASHIPs regularly receive claims data from all ASHIP-associated physicians for ambulatory services, covering more than 85% of the total population in Germany.</s><s>Within the ASHIP vaccination monitoring project, anonymous data of ASHIPs are transferred to the Robert Koch Institute (RKI) on a quarterly basis and include information on age (month/year), date of patient contact, as well as date and type of vaccination <ref type="bibr" target="#b27">[27]</ref>.</s><s>We extracted information on seasonal influenza vaccination for seasons 2010/11, 2011/12 and 2012/13 among all individuals aged 60+ years and calculated VC for the total elderly population and by age-strata.</s><s>Data were available from 16 of the 17 ASHIP regions.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Identification of influenza cases</head><p><s>In Germany, laboratory-confirmed influenza infections are notifiable according to the German Protection against Infection Act since 2001 <ref type="bibr" target="#b28">[28]</ref>.</s><s>We identified influenza cases through the national communicable disease reporting system.</s><s>Within this system, case-based data of patients with laboratory-confirmed influenza infection are collected by local public health authorities and transmitted electronically via state health departments to RKI.</s><s>Cases reports include information on age (month/year), place of residence, date of disease onset, date of notification, receipt of influenza vaccine, laboratory confirmation of disease, influenza type and subtype, and hospitalization.</s><s>Additional information, such as type or name of the influenza vaccine is rarely reported and information on comorbidities is almost never provided.</s></p><p><s>For our analysis, notified cases aged 60 years and older were included if infection was laboratory-confirmed (i.e., detection of influenza antigens using enzyme immunoassays, polymerase chain reaction, or virus culture), and if information on cases' vaccination status was available.</s></p><p><s>A case was defined as vaccinated, if classified as "vaccinated in this current season" in the electronic surveillance system.</s><s>An exact date of vaccination was provided for 66% of all vaccinated influenza cases between 2010/11-2012/13, of whom only 9 had a symptom onset &lt;14 days post vaccination.</s><s>These cases were considered as "nonvaccinated".</s><s>For the remaining 34% of vaccinated cases, for whom the date of vaccination was missing, the number of persons with disease onset within 14 days after vaccination was regarded as unlikely.</s><s>Since this assumption can potentially increase the numbers of vaccine failures and decrease VE thereby, we conducted a sensitivity analysis by excluding people from the analysis who were vaccinated &lt;14 days prior to symptom onset (results are presented in Additional file 1: Table <ref type="table" target="#tab_0">S1</ref>).</s><s>For each season, proportion of laboratory confirmed influenza cases vaccinated with 95% CIs stratified by age-group (60+, 60-69, 70-79, 80+ years), influenza subtype and hospitalization status (yes/no) were calculated.</s></p><p><s>The data on influenza cases reported under the German Protection against Infection Act are freely available from the national surveillance database at https://survstat.rki.de.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Definition of influenza seasons</head><p><s>We included cases with disease onset during the study period that was defined from week 40 of the previous to week 20 of the following year for each of the three seasons under investigation.</s><s>In a sensitivity analysis, we restricted VE calculation to cases with disease onset during the respective influenza season as defined by RKI's Working Group for Influenza.</s><s>According to the Working Group, which collects syndromic and laboratory data within a sentinel system of primary care physicians in Germany, influenza seasons were defined from weeks 50/2010-14/2011, 6/2012-16/2012 and 50/2012-16/2013, respectively <ref type="bibr" target="#b29">[29,</ref><ref type="bibr" target="#b30">30]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>We used descriptive analysis for seasonal influenza VC.</s><s>In brief, VCs and 95% CIs were calculated as proportion of patients having received claimed influenza vaccinations among the total statutory health insured population by region, age-group, and season.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Calculation of vaccine effectiveness (VE)</head><p><s>VE and 95% CIs were calculated using the screening method according to Farrington <ref type="bibr" target="#b25">[25]</ref> with the following formula:</s></p><formula xml:id="formula_0">V E ¼ PV −PCV PV 1 −PCV ð Þ</formula><p><s>where PV is the proportion population vaccinated (i.e.</s><s>VC) in the respective age-group and where PCV is the proportion of cases vaccinated.</s><s>We calculated VE by season, age-group, hospitalization status, and influenza subtype.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Identification of factors associated with vaccine failure</head><p><s>We defined vaccine failure as a laboratory-confirmed influenza infection in a person vaccinated against influenza in the respective season.</s><s>To examine independent predictors of breakthrough infections (leading to vaccine failure) for each influenza season and by influenza subtype, we used a logistic regression model including potential confounding factors (age, sex, hospitalization, week since start of influenza season) and calculated odds ratios (OR) and 95% CI.</s><s>Two-sided hypothesis tests were performed and a p-value of ≤0.05 was considered statistically significant.</s><s>The statistical software package STATA®, version 11 (STATA Corp., College Station, TX, USA) was used.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Identification of observational VE studies from Europe</head><p><s>To compare our study results with influenza VE estimates among the elderly in other observational studies in Europe, we conducted a systematic literature search in PubMed using the following search strategy: (((influenza) AND vaccine) AND effectiveness) AND Europe (restrictions: publication year 2010 to 2015; language: English; species: human).</s><s>Date of last search was 17 February 2015.</s><s>In addition, we complemented our search strategy by comparing identified studies with those identified by a recently published meta-analysis by Darvishian et al. <ref type="bibr" target="#b31">[31]</ref>.</s><s>Only studies were included that reported subtype-specific VE estimates in at least one of the seasons 2010/11-2012/13.</s><s>We extracted (subtype-specific) VE estimates and compared these results with ours.</s><s>We excluded studies which used other designs than the TND and studies providing "early", "mid-season", or "interim estimates".</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethical considerations and data protection</head><p><s>Since we analyzed (i) anonymous VC-data from ASHIP and (ii) anonymous data on influenza cases that are collected routinely within the German surveillance system for notifiable diseases, ethical approval was not obtained.</s><s>The Federal Commissioner for Data Protection and Freedom of Information in Germany has approved the ASHIP vaccination monitoring project.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Standards of reporting</head><p><s>We followed the STROBE guidelines in reporting this study <ref type="bibr" target="#b32">[32]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Influenza vaccination coverage among the elderly 2010/11-2012/13</head><p><s>VC by age-group and season is shown in Table <ref type="table" target="#tab_0">1</ref>.</s><s>Over the three seasons, VC decreased slightly in all age-groups.</s><s>In the age-group 60+ years, the VC assessment based on data from an average 18 million (i.e.</s><s>~85% of the total 22 million) individuals of this age-group living in Germany.</s><s>VC in this age-group ranged between 37% and 44% and increased with age (Table <ref type="table" target="#tab_0">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Notified influenza cases aged ≥60 years, 2010/11-2012/13</head><p><s>In total 1,371 (2010/11), 1,034 (2011/12) and 6,803 (2012/13) laboratory-confirmed influenza cases aged 60+ were notified to the RKI during the study period, respectively.</s><s>The high number of laboratory-confirmed cases in the season 2012/13 reflected the severity of the influenza wave in this particular season in Germany <ref type="bibr" target="#b29">[29]</ref>.</s><s>Among all notified cases, information on laboratory confirmation was available in more than 96%, and information on vaccination status was available in more than 75%.</s><s>In the final analysis we included 1,174 (85.6%) cases in the season 2010/11, 767 (74.1%) cases in the season 2011/12, and 5,217 (76.7%) cases in the season 2012/13, respectively.</s><s>In two seasons (2011/12 and 2012/13), excluded cases were older than included cases and in the season 2012/13, excluded cases were more likely to be hospitalized (40% vs 44%, p = 0.01; for details see online Additional file 1: Table <ref type="table" target="#tab_1">S2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Characteristics of included influenza cases aged ≥60 years</head><p><s>Characteristics of included influenza cases are shown in Table <ref type="table" target="#tab_1">2</ref>. Proportions of cases vaccinated ranged from 14% in season 2010/11 to 27% in season 2011/12.</s><s>In two seasons (2010/11 and 2012/13), subtype A(H1N1)pdm was the dominant influenza A virus.</s><s>The season 2011/12 was dominated by subtype A(H3N2).</s></p><p><s>Overall, for 66.2% of cases information on the date of vaccination was available.</s><s>Among these vaccinated cases, only four (2.4%), one (0.5%) and four (0.4%) in the season 2010/11, 2011/12 and 2012/13, respectively, were considered as non-vaccinated, since onset of disease occurred within 14 days after vaccination.</s><s>Excluding these nine cases from analysis did not affect VE estimates (for details see online Additional file 1: Table <ref type="table" target="#tab_0">S1</ref>).</s><s>Approximately 40% of cases were notified as hospitalized in each season.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Vaccine effectiveness</head><p><s>Table <ref type="table" target="#tab_2">3</ref> provides data on VE estimates in individuals aged 60+ stratified by influenza subtypes, age-group and hospitalization status for all seasons.</s><s>In the season 2010/ 11, VE was 76% (95% CI, 70-81%) for the predominantly circulating influenza A(H1N1)pdm and 84% (95% CI, 76-90%) for influenza B. VE increased with age for both subtypes and were higher in hospitalized compared to nonhospitalized patients.</s><s>In the season 2011/12, VE was 87% (95% CI, 14-100%) for A(H1N1)pdm, −9% (95% CI, −59-26%) for influenza A(H3N2) and 74% (95% CI, 55-86%) for influenza B. VE estimates against influenza A(H3N2) decreased with age, and were higher among hospitalized compared to non-hospitalized cases.</s><s>However, a statistically significant protective effect against laboratory confirmed A(H3N2) infection was not observed.</s><s>In the season 2012/13, VE was 74% (95% CI, 69-79) for influenza A(H1N1)pdm, 39% (95% CI, 13-58%) for influenza  A(H3N2) and 73% (95% CI, 68-77%) for influenza B. In this season, VE estimates against influenza A(H3N2) decreased with age and showed no protective effect in individuals aged 80 and older and among non-hospitalized cases.</s><s>For the sensitivity analysis, in total 1,168 (99.4%), 664 (86.6%) and 5,182 (99.3%) cases were included when applying a narrower definition for the influenza seasons.</s></p><p><s>In none of the seasons did VE estimates differed by more than 3% from those calculated in the primary analysis (data not shown).</s><s>Further sensitivity analyses, e.g., assuming that influenza vaccination coverage (VC) among excluded cases was 50% or 200% of VC among included cases, or assuming that 50% of cases with missing information on the exact date of vaccination were regarded as non-vaccinated are shown in the online supplement (Additional file 1: Tables <ref type="table" target="#tab_5">S3-S5</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Factors associated with vaccine failure</head><p><s>In all three seasons, factors independently associated with vaccine failure were identified among influenza A cases only (Table <ref type="table" target="#tab_3">4</ref>).</s><s>The odds for a breakthrough disease increased with age (p ≤0.05 for all three seasons).</s><s>In addition, in all seasons vaccine failures was significantly less common among hospitalized compared to non-  <ref type="bibr" target="#b17">[17,</ref><ref type="bibr" target="#b33">[33]</ref><ref type="bibr" target="#b34">[34]</ref><ref type="bibr" target="#b35">[35]</ref><ref type="bibr" target="#b36">[36]</ref><ref type="bibr" target="#b37">[37]</ref><ref type="bibr" target="#b38">[38]</ref><ref type="bibr" target="#b39">[39]</ref><ref type="bibr" target="#b40">[40]</ref><ref type="bibr" target="#b41">[41]</ref><ref type="bibr" target="#b42">[42]</ref><ref type="bibr" target="#b43">[43]</ref><ref type="bibr" target="#b44">[44]</ref><ref type="bibr" target="#b45">[45]</ref><ref type="bibr" target="#b46">[46]</ref><ref type="bibr" target="#b47">[47]</ref><ref type="bibr" target="#b48">[48]</ref>.</s><s>In all seasons and for all influenza-subtypes, VE estimates from our study were close or within the 95% CI of almost all identified TND studies (Table <ref type="table" target="#tab_4">5</ref>).</s><s>Of particular interest, the included studies did not identify a protective effect against laboratory-confirmed influenza A(H3N2) infection in the 2011/12 season <ref type="bibr" target="#b39">[39,</ref><ref type="bibr" target="#b41">41,</ref><ref type="bibr" target="#b49">49]</ref> and no or low VE for the 2012/13 season <ref type="bibr" target="#b35">[35,</ref><ref type="bibr" target="#b37">37,</ref><ref type="bibr" target="#b44">44]</ref>, similar to what we have observed in our analysis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>In this study we were able to show that among the elderly VE against influenza A(H1N1)pdm and B was moderate in all three seasons 2010/11-2012/13, whereas VE against influenza A(H3N2) was low in two consecutive seasons.</s><s>These VE estimates were comparable to results provided by other observational studies in Europe that used the TND, suggesting that the screening method can be a suitable tool to generate useful influenza VE estimates at least for this particular age-group.</s></p><p><s>In studies applying the TND, patients with medically attended acute respiratory illness are recruited into the study and -if performed in an appropriate way-systematically tested for influenza virus.</s><s>Those with laboratoryconfirmed influenza infection are defined as cases and otherwise as controls.</s><s>Since both groups are recruited in one process and both derived from the same population the TND has been found to be less susceptible to bias <ref type="bibr" target="#b19">[19]</ref>.</s><s>In the absence of RCTs, the TND has been advocated as a valid method to calculate almost unbiased influenza VE estimates <ref type="bibr" target="#b18">[18,</ref><ref type="bibr" target="#b50">50]</ref> under a wide range of assumptions <ref type="bibr" target="#b51">[51]</ref>.</s><s>As with all observational studies adjusting for important confounders has still to be performed <ref type="bibr" target="#b18">[18]</ref>.</s><s>However, in particular for the age-group 60+ there are often only small differences between crude and adjusted point estimates as shown in most of the observational studies identified in our study <ref type="bibr" target="#b17">[17,</ref><ref type="bibr" target="#b35">35,</ref><ref type="bibr" target="#b38">38,</ref><ref type="bibr" target="#b40">40,</ref><ref type="bibr" target="#b43">43]</ref>.</s></p><p><s>The screening method has been described as a rapid and cheap tool to survey vaccine effectiveness, particularly when denominator data on individuals are not available <ref type="bibr" target="#b25">[25,</ref><ref type="bibr" target="#b26">26]</ref>.</s><s>For the screening method, only a random sample of cases is needed.</s><s>However, accurate and age-group specific VC rates are crucial to produce valid VE estimates <ref type="bibr" target="#b25">[25,</ref><ref type="bibr" target="#b52">52]</ref>.</s><s>In our study, the random sample derived from the national communicable disease reporting system.</s><s>Although this system collects data on laboratory-confirmed influenza infections nationwide, selection bias (e.g., enhanced testing for influenza among chronically ill patients), observer bias (e.g., vaccinated cases are less likely to be swabbed for influenza) or reporting bias (e.g., differences in notification behavior among physicians) cannot completely be ruled out.</s><s>In addition, data on important confounders are not systematically reported in the system and adjusting for these  Adjusted -variables was not possible.</s><s>However, we probably reduced the impact of these shortcomings since we calculated VE for small age strata among elderly patients, for whom annual influenza vaccination is generally recommended in Germany.</s><s>Since our results were rather similar to those from studies using the TND, it can be hypothesized that in this particular age-group adjustment for underlying medical conditions might not play such an important role.</s><s>Furthermore, age-group specific VC rates were calculated in our study from a large database of health insurance claims covering the majority of the German population.</s><s>The database has been shown to be a valid and representative instrument to describe VC in various age-groups in Germany <ref type="bibr" target="#b27">[27,</ref><ref type="bibr" target="#b53">53]</ref> -a prerequisite for valid VE estimates when the screening method is applied <ref type="bibr" target="#b25">[25]</ref>.</s></p><p><s>Due to the large sample size we were able to assess subtype-specific VE even in different age-strata within the elderly population.</s><s>In contrast, in observational studies using the TND estimation of strain-specific VE in the elderly is often not possible or limited by large CIs <ref type="bibr" target="#b17">[17,</ref><ref type="bibr" target="#b35">35,</ref><ref type="bibr" target="#b36">36,</ref><ref type="bibr" target="#b42">42,</ref><ref type="bibr" target="#b54">54]</ref>.</s><s>Furthermore, the assessment of VE against severe influenza using the TND is possible but would require additional study sites in hospitals and is often logistically challenging and resource-demanding.</s><s>In view of these strengths and limitations, the screening method can be regarded as an useful method for the rapid assessment of crude influenza VE in the elderly when data on laboratory-confirmed influenza cases are available.</s></p><p><s>In our study, one of the major findings was that VE against influenza A(H3N2) was low in two consecutive seasons.</s><s>This finding confirms the results from previous studies where no or only little protective effect against influenza A(H3N2) was observed <ref type="bibr" target="#b35">[35,</ref><ref type="bibr" target="#b37">37,</ref><ref type="bibr" target="#b39">39,</ref><ref type="bibr" target="#b41">41,</ref><ref type="bibr" target="#b44">44,</ref><ref type="bibr" target="#b49">49]</ref>.</s></p><p><s>Since antigenetic changes of the A/Victoria/361/2011 (H3N2)-like vaccine during the manufacturing process has been reported, the WHO has recommended that the influenza A(H3N2) vaccine component for use in the 2013/14 season should be updated <ref type="bibr" target="#b55">[55]</ref>.</s></p><p><s>In addition to older age, the probability of vaccine failure increased over time during season 2011/12 among cases infected with influenza A(H3N2).</s><s>The same effect has been observed in other settings and it was discussed that this may be due to virus changes or waning immunity after vaccination <ref type="bibr" target="#b39">[39,</ref><ref type="bibr" target="#b41">41,</ref><ref type="bibr" target="#b49">49]</ref>.</s><s>Due to the higher mutation rate of influenza A compared to B viruses <ref type="bibr" target="#b56">[56]</ref> it is plausible that these effects are mainly identified among patients infected with influenza A.</s></p><p><s>Interestingly, we found that vaccine failure was negatively associated with hospitalization.</s><s>This was true in all seasons among cases infected with influenza A viruses.</s><s>A recently conducted study in Spain suggested that VE may be greater in preventing severe than in preventing mild cases, and that the benefits of vaccination may be greater than suggested <ref type="bibr" target="#b57">[57]</ref>.</s><s>However, in our study we cannot fully exclude that this effect was due to bias, e.g. the healthy vaccinee effect or different testing behavior for influenza in vaccinated inpatients and vaccinated outpatients.</s><s>Further studies exploring these potential VE differences by clinical outcome would be important to better estimate the true effect of influenza vaccination in preventing severe influenza and influenza-related mortality.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strengths and limitations</head><p><s>Our study benefits from its large sample size.</s><s>During three consecutive influenza seasons we were able to include more than 7,000 laboratory-confirmed influenza cases aged 60+ both from the outpatient and inpatient sector.</s><s>Due to this large size we were able to assess subtype-specific VE even in age-strata of those aged 80+.</s></p><p><s>In addition, since we used age-specific VC data for each single season derived from a large database representing ~85% of the German population, VC can be regarded as representative.</s><s>Finally, by limiting the studies to individuals aged 60+ we were probably able to reduce the risk of biases to at least some extent, which was reflected by similar VE estimates when comparing to studies using the TND.</s><s>However, some limitations have to be acknowledged.</s><s>First, cases were identified by the mandatory disease surveillance system and the quality of our analysis depends on the quality of the reported data transmitted to the RKI.</s><s>Since only laboratory-confirmed infections are notifiable in Germany and since it is the decision of the physician whether or not to swab patients for influenza, we cannot exclude that vaccinated persons were less likely be tested for influenza virus infection, which might have led to an overestimation of VE.</s><s>However, this would not explain differences in VE between hospitalized and non-hospitalized cases.</s><s>Second, cases were defined as vaccinated if they were notified as "currently vaccinated" and considered as non-vaccinated if disease onset occurred within 14 days after vaccination.</s><s>Since date of vaccination was provided by 66% of all cases only, it is possible that in cases with unknown vaccination date disease occurred within 14 days after receipt of the vaccine leading to an underestimation of VE.</s><s>However, since the proportion among cases with information on vaccination date with disease onset prior 14 days after receipt of vaccine was less than 1%, it seems rather unlikely that this proportion was significantly higher among those without information on vaccination date.</s><s>Third, we were not able to control for some important confounders such as comorbidities, but limiting our study population to persons aged 60+ might have accounted for this.</s><s>Fourth, although &gt;85% of all cases were laboratory confirmed using PCR or cellculture, subtyping was only performed in 70% of cases.</s><s>Finally, since vaccine types are not reported systematically for notified influenza cases, vaccine type or product specific VE cannot be calculated.</s><s>Overall, optimizing the completeness of the data regarding hospitalization status, vaccination status, and date of vaccination as well as additional information on comorbidities could improve the validity of our VE estimates.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>In conclusion, the screening method can be used to rapidly assess influenza subtype-specific VE among the elderly in Germany.</s><s>Due to high numbers of cases, VE can be estimated even for rather narrow age-ranges and nondominating influenza subtypes within the elderly population as well as for hospitalized and non-hospitalized patients.</s><s>Since adjusting for important confounders and the assessment of product-specific VE is not possible, the screening method can be regarded as an important but only supplementary tool for assessing crude VE, in addition to more precise but also more resourcedemanding TND-studies for the post-marketing evaluation of influenza vaccines.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Seasonal influenza vaccination coverage by age group estimated from health insurance claims data, influenza seasons 2010/11-2012/13, Germany* Upper and lower bounds of the 95% CIs were 0.2% points above or below the point estimates and are not shown in the tables.</s></p></div></figDesc><table><row><cell>Age-group</cell><cell>2010/11</cell><cell>2011/12</cell><cell>2012/13</cell></row><row><cell>or place of</cell><cell>%</cell><cell>%</cell><cell>%</cell></row><row><cell>residence</cell><cell></cell><cell></cell><cell></cell></row><row><cell>≥18 years</cell><cell>21.0</cell><cell>19.8</cell><cell>17.4</cell></row><row><cell>≥60 years</cell><cell>44.0</cell><cell>42.1</cell><cell>37.4</cell></row><row><cell>60-69 years</cell><cell>35.9</cell><cell>33.0</cell><cell>28.2</cell></row><row><cell>70-79 years</cell><cell>48.3</cell><cell>46.7</cell><cell>42.1</cell></row><row><cell>≥80 years</cell><cell>51.4</cell><cell>50.6</cell><cell>45.6</cell></row></table><note><p><s>*</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Characteristics of laboratory-confirmed influenza cases aged 60+ years included in the analysis, influenza seasons 2010/11-2012/13, Germany</s></p></div></figDesc><table><row><cell></cell><cell>2010/11</cell><cell>2011/12</cell><cell>2012/13</cell></row><row><cell></cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell></row><row><cell>Total</cell><cell>1,174 (100)</cell><cell>767 (100)</cell><cell>5,217 (100)</cell></row><row><cell>Cases vaccinated</cell><cell>162 (14.0)</cell><cell>208 (27.1)</cell><cell>921 (17.7)</cell></row><row><cell>Influenza subtypes</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Influenza type A</cell><cell>774 (65.9)</cell><cell>537 (70.0)</cell><cell>3,069 (58.8)</cell></row><row><cell>Influenza type B</cell><cell>251 (21.4)</cell><cell>97 (12.7)</cell><cell>1,267 (24.3)</cell></row><row><cell>Influenza A/B 1</cell><cell>137 (11.7)</cell><cell>89 (11.6)</cell><cell>806 (15.5)</cell></row><row><cell>No data</cell><cell>12 (1.0)</cell><cell>44 (5.8)</cell><cell>75 (1.4)</cell></row><row><cell>Influenza strains</cell><cell></cell><cell></cell><cell></cell></row><row><cell>A(H1N1)pdm</cell><cell>582 (49.6)</cell><cell>12 (1.6)</cell><cell>859 (16.5)</cell></row><row><cell>A(H3N2)</cell><cell>1 (0.1)</cell><cell>118 (15.4)</cell><cell>168 (3.2)</cell></row><row><cell>B</cell><cell>251 (21.4)</cell><cell>97 (12.7)</cell><cell>1267 (24.3)</cell></row><row><cell>Not genotyped</cell><cell>137 (11.7)</cell><cell>89 (11.6)</cell><cell>806 (15.5)</cell></row><row><cell>Missing data on strains</cell><cell>203 (17.3)</cell><cell>451 (58.8)</cell><cell>2117 (40.6)</cell></row><row><cell>Men (%)</cell><cell>589 (50.2)</cell><cell>306 (40.0)</cell><cell>2440 (46.8)</cell></row><row><cell>Age in years (mean ± SD)</cell><cell>67.2 (±6.9)</cell><cell>74.7 (±9.9)</cell><cell>71.2 (±8.9)</cell></row><row><cell>Age-group (years)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>60-69</cell><cell>797 (67.9)</cell><cell>263 (34.3)</cell><cell>2485 (47.6)</cell></row><row><cell>70-79</cell><cell>307 (26.2)</cell><cell>267 (34.8)</cell><cell>1736 (33.3)</cell></row><row><cell>≥80</cell><cell>70 (6.0)</cell><cell>237 (30.9)</cell><cell>996 (19.1)</cell></row><row><cell>Hospitalization status</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Hospitalized</cell><cell>455 (38.8)</cell><cell>317 (41.5)</cell><cell>2060 (39.5)</cell></row><row><cell>Not hospitalized</cell><cell>709 (60.4)</cell><cell>446 (58.5)</cell><cell>3087 (59.2)</cell></row></table><note><p><s>Data may not add up to 100% due to missing data. 1 Reported as influenza, type A/B, not specified.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3</head><label>3</label><figDesc><div><p><s>Vaccine effectiveness (VE in %) against laboratory-confirmed influenza stratified by influenza-subtype, age-groups and hospitalization status, season 2010/11-2012/13, Germany</s></p></div></figDesc><table><row><cell>Age-group (years)</cell><cell>Season 2010/11</cell><cell>Season 2011/2012</cell><cell>Season 2012/2013</cell></row><row><cell>VE against influenza (all types)</cell><cell>n = 1,174</cell><cell>n = 767</cell><cell>n = 5,217</cell></row><row><cell>60-69</cell><cell>72 (65-77)</cell><cell>59 (43-71)</cell><cell>65 (61-69)</cell></row><row><cell>70-79</cell><cell>82 (75-87)</cell><cell>56 (43-67)</cell><cell>63 (58-67)</cell></row><row><cell>≥80</cell><cell>86 (71-94)</cell><cell>40 (22-55)</cell><cell>60 (54-66)</cell></row><row><cell>≥60</cell><cell>80 (76-83)</cell><cell>49 (39-57)</cell><cell>64 (63-67)</cell></row><row><cell>≥60 non-hospitalized</cell><cell>77 (72-81) 1</cell><cell>37 (22-49) 2</cell><cell>63 (59-66) 1</cell></row><row><cell>≥60 hospitalized</cell><cell>83 (78-88) 1</cell><cell>62 (51-72) 2</cell><cell>67 (63-71) 1</cell></row><row><cell>VE against influenza A</cell><cell>n = 774</cell><cell>n = 537</cell><cell>n = 3,069</cell></row><row><cell>60-79</cell><cell>75 (69-80)</cell><cell>55 (43-65)</cell><cell>62 (58-66)</cell></row><row><cell>≥80</cell><cell>86 (64-96)</cell><cell>36 (11-54)</cell><cell>54 (44-62)</cell></row><row><cell>≥60</cell><cell>77 (72-81)</cell><cell>46 (35-56)</cell><cell>60 (57-64)</cell></row><row><cell>≥60 non-hospitalized</cell><cell>72 (64-79) 2</cell><cell>32 (14-47) 2</cell><cell>57 (52-62) 2</cell></row><row><cell>≥60 hospitalized</cell><cell>82 (75-88) 2</cell><cell>63 (49-74) 2</cell><cell>66 (61-71) 2</cell></row><row><cell>VE against influenza A (H1N1)pdm</cell><cell>n = 582</cell><cell>n = 12</cell><cell>n = 859</cell></row><row><cell>60-79</cell><cell>74 (67-79)</cell><cell>85 (−6-100)</cell><cell>74 (68-79)</cell></row><row><cell>≥80</cell><cell>91 (63-99)</cell><cell>NA 3</cell><cell>64 (39-80)</cell></row><row><cell>≥60</cell><cell>76 (70-81)</cell><cell>87 (14-100)</cell><cell>74 (69-79)</cell></row><row><cell>≥60 non-hospitalized</cell><cell>68 (58-76) 2</cell><cell>NA 3</cell><cell>70 (62-77) 1</cell></row><row><cell>≥60 hospitalized</cell><cell>83 (76-89) 2</cell><cell>NA 3</cell><cell>80 (72-86) 1</cell></row><row><cell>VE against influenza A (H3N2)</cell><cell>n = 1</cell><cell>n = 118</cell><cell>n = 168</cell></row><row><cell>60-79</cell><cell>NA 3</cell><cell>33 (−16-63)</cell><cell>47 (18-66)</cell></row><row><cell>≥80</cell><cell>NA 3</cell><cell>−49 (−171-17)</cell><cell>22 (−49-60)</cell></row><row><cell>≥60</cell><cell>NA 3</cell><cell>−9 (−59-26)</cell><cell>39 (13-58)</cell></row><row><cell>≥60 non-hospitalized</cell><cell>NA 3</cell><cell>−48 (−132-5) 2</cell><cell>27 (−8-51) 2</cell></row><row><cell>≥60 hospitalized</cell><cell>NA 3</cell><cell>56 (−1-83) 2</cell><cell>73 (30-92) 2</cell></row><row><cell>VE against influenza B</cell><cell>n = 251</cell><cell>n = 97</cell><cell>n = 1,267</cell></row><row><cell>60-79</cell><cell>83 (74-89)</cell><cell>73 (49-86)</cell><cell>74 (69-79)</cell></row><row><cell>≥80</cell><cell>89 (55-99)</cell><cell>80 (8-98)</cell><cell>66 (52-75)</cell></row><row><cell>≥60</cell><cell>84 (76-90)</cell><cell>73 (54-85)</cell><cell>73 (68-77)</cell></row><row><cell>≥60 non-hospitalized</cell><cell>82 (72-89) 1</cell><cell>73 (42-89) 1</cell><cell>75 (69-80) 1</cell></row><row><cell>≥60 hospitalized</cell><cell>87 (73-95) 1</cell><cell>72 (39-89) 1</cell><cell>69 (61-77) 1</cell></row><row><cell cols="2">1 Not-hospitalized vs. hospitalized statistically not significant (p &gt; 0.05).</cell><cell></cell><cell></cell></row></table><note><p><s>2Not-hospitalized vs. hospitalized statistically significant (p ≤ 0.05).3No/lownumber of cases.hospitalized</s><s>influenza A cases.</s><s>Finally, a longer time period since start of the influenza season increased the odds of a A(H3N2) breakthrough infection, but only in the season 2011/12.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4</head><label>4</label><figDesc><div><p><s>Factors independently associated with seasonal influenza vaccine failures among cases aged 60 years and older, Germany, seasons 2010/11-2012/13</s></p></div></figDesc><table><row><cell>Season</cell><cell>Influenza-type</cell><cell>Variable/Category</cell><cell>Adjusted OR (95% CI)</cell><cell>p-value</cell></row><row><cell>2010/11</cell><cell>A(H1N1)</cell><cell>Age in years</cell><cell>1.03 (1.00-1.07)</cell><cell>0.04</cell></row><row><cell></cell><cell></cell><cell>Weeks since begin influenza season 1</cell><cell>1.02 (0.94-1.11)</cell><cell>0.67 2</cell></row><row><cell></cell><cell></cell><cell>Hospitalization</cell><cell>0.45 (0.28-0.73)</cell><cell>&lt;0.01</cell></row><row><cell>2011/12</cell><cell>A(H3N2)</cell><cell>Age in years</cell><cell>1.07 (1.03-1.12)</cell><cell>&lt;0.01</cell></row><row><cell></cell><cell></cell><cell>Weeks since begin influenza season 1</cell><cell>1.12 (1.01-1.26)</cell><cell>0.03</cell></row><row><cell></cell><cell></cell><cell>Hospitalization</cell><cell>0.23 (0.09-0.62)</cell><cell>&lt;0.01</cell></row><row><cell>2012/13</cell><cell>A(H1N1)</cell><cell>Age in years</cell><cell>1.05 (1.02-1.08)</cell><cell>&lt;0.01</cell></row><row><cell></cell><cell></cell><cell>Weeks since begin influenza season 1</cell><cell>1.02 (0.95-1.11)</cell><cell>0.49 2</cell></row><row><cell></cell><cell></cell><cell>Hospitalization</cell><cell>0.51 (0.33-0.80)</cell><cell>&lt;0.01</cell></row><row><cell></cell><cell>A(H3N2)</cell><cell>Age in years</cell><cell>1.06 (1.02-1.11)</cell><cell>&lt;0.01</cell></row><row><cell></cell><cell></cell><cell>Weeks since begin influenza season 1</cell><cell>1.11 (0.98-1.26)</cell><cell>0.08 2</cell></row><row><cell></cell><cell></cell><cell>Hospitalization</cell><cell>0.35 (0.12-1.00)</cell><cell>0.05</cell></row><row><cell cols="3">OR, Odds ratio; 95% CI, 95% confidence interval; ns, not statistically significant.</cell><cell></cell><cell></cell></row></table><note><p><s>1Influenza season defined as from week 40 of the previous year to week 20 in the following year.2Removing</s><s>this (non-significant) variable did not influence the final model.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 5</head><label>5</label><figDesc><div><p><s>Vaccine effectiveness (VE) against influenza subtypes among the elderly: comparison of results from this present study with results from observational studies in Europe using the test-negative design, seasons 2010/11-2012/13</s></p></div></figDesc><table><row><cell>Country [ref]</cell><cell>Age-group</cell><cell></cell><cell>VE  § in %</cell><cell>VE  § in %</cell><cell>VE  § in %</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(95% CI)</cell><cell>(95% CI)</cell><cell>(95% CI)</cell></row><row><cell></cell><cell>(Years)</cell><cell>VE-analysis</cell><cell>A(H1N1)pdm</cell><cell>A(H3N2)</cell><cell>B</cell></row><row><cell>Season 2010/11</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>This study</cell><cell>≥60</cell><cell>Crude</cell><cell>76 (70-81)</cell><cell>-</cell><cell>84 (76-90)</cell></row><row><cell></cell><cell></cell><cell>Adjusted</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell>Europe (I-MOVE) 1 [38]</cell><cell>≥60</cell><cell>Crude</cell><cell>73 (48-86)</cell><cell>-</cell><cell>48 (−2-73)</cell></row><row><cell></cell><cell></cell><cell>Adjusted</cell><cell>72 (27-90)</cell><cell>-</cell><cell>56 (−38-86)</cell></row><row><cell>UK [42]</cell><cell>≥65</cell><cell>Crude</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell></cell><cell></cell><cell>Adjusted</cell><cell>70 (0-85) 2</cell><cell>-</cell><cell>65 (20-80) 2</cell></row><row><cell>Spain I [40]</cell><cell>≥50</cell><cell>Crude</cell><cell>67 (27-85) 3</cell><cell>-</cell><cell>-</cell></row><row><cell></cell><cell></cell><cell>Adjusted</cell><cell>69 (0-91) 3</cell><cell>-</cell><cell>-</cell></row><row><cell>Spain II [43]</cell><cell>≥60</cell><cell>Crude</cell><cell>60 (20-80) 4</cell><cell>-</cell><cell>-</cell></row><row><cell></cell><cell></cell><cell>Adjusted</cell><cell>59 (16-76) 4</cell><cell>-</cell><cell>-</cell></row><row><cell>Spain III [45]</cell><cell>≥65</cell><cell>Crude</cell><cell>41 (−36-74) 5</cell><cell>-</cell><cell>-</cell></row><row><cell></cell><cell></cell><cell>Adjusted</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell>Spain IV [46]</cell><cell>≥65</cell><cell>Crude</cell><cell>54 (−18-82) 6</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>Adjusted</cell><cell>-</cell><cell></cell><cell></cell></row><row><cell>Germany [17]</cell><cell>≥60</cell><cell>Crude</cell><cell>89 (1-99) 3</cell><cell>-</cell><cell>-</cell></row><row><cell></cell><cell></cell><cell>Adjusted</cell><cell>92 (−67-100) 3</cell><cell>-</cell><cell>-</cell></row><row><cell>Season 2011/12</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>This study</cell><cell>≥60</cell><cell>Crude</cell><cell>87 (14-100)</cell><cell>−9 (−59-26)</cell><cell>74 (55-86)</cell></row><row><cell></cell><cell></cell><cell>Adjusted</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell>Europe (I-MOVE) 1 [39]</cell><cell>≥60</cell><cell>Crude</cell><cell>-</cell><cell>6 (−41-38)</cell><cell>-</cell></row><row><cell></cell><cell></cell><cell>Adjusted</cell><cell>-</cell><cell>15 (−33-46)</cell><cell>-</cell></row><row><cell>UK [41]</cell><cell>≥65</cell><cell>Crude</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell></cell><cell></cell><cell>Adjusted</cell><cell>-</cell><cell>48 (−50-82)</cell><cell>-</cell></row><row><cell>Spain I [49]</cell><cell>≥65</cell><cell>Crude</cell><cell>-</cell><cell>4 (−106-55) 7</cell><cell>-</cell></row><row><cell></cell><cell></cell><cell>Adjusted</cell><cell>-</cell><cell>19 (−146-73) 7</cell><cell>-</cell></row><row><cell>Spain II 8 [47]</cell><cell>≥65</cell><cell>Crude</cell><cell>-</cell><cell>26 (−69-78)</cell><cell>-</cell></row><row><cell></cell><cell></cell><cell>Adjusted</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell>Season 2012/13</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>This study</cell><cell>≥60</cell><cell>Crude</cell><cell>74 (69-79)</cell><cell>39 (13-58)</cell><cell>73 (68-77)</cell></row><row><cell></cell><cell></cell><cell>Adjusted</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell>Europe (I-MOVE) 1 [37]</cell><cell>≥60</cell><cell>Crude</cell><cell>59 (14-80)</cell><cell>37 (−13-65)</cell><cell>44 (9-66)</cell></row><row><cell></cell><cell></cell><cell>Adjusted</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell>UK [44]</cell><cell>≥65</cell><cell>Crude</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell></cell><cell></cell><cell>Adjusted</cell><cell></cell><cell>−14 (−206-57)</cell><cell>65 (18-85)</cell></row><row><cell>Denmark [35]</cell><cell>≥65</cell><cell>Crude</cell><cell>-</cell><cell>−19 (−52-6)</cell><cell>64 (17-84)</cell></row><row><cell></cell><cell></cell><cell>Adjusted</cell><cell>-</cell><cell>−11 (−41-14)</cell><cell>69 (26-87)</cell></row><row><cell>Lithuania 8 [48]</cell><cell>≥60</cell><cell>Crude</cell><cell>92 (−55-100) 9</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 5</head><label>5</label><figDesc><div><p><s>Vaccine effectiveness (VE) against influenza subtypes among the elderly: comparison of results from this present study with results from observational studies in Europe using the test-negative design, seasons 2010/11-2012/13 (Continued) MOVE pooled data from other European countries; therefore, overlapping with some of the individual studies from the same season is likely.</s></p></div></figDesc><table><row><cell>Portugal 8 [33]</cell><cell>≥60</cell><cell>Crude</cell><cell>80 (19-95) 10</cell><cell>-</cell><cell>-</cell></row><row><cell></cell><cell></cell><cell>Adjusted</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell>Multicenter 11 [34]</cell><cell>≥65</cell><cell>Crude 12</cell><cell>34 (−22-64)</cell><cell>46 (−16-75)</cell><cell>46 (23-63)</cell></row><row><cell></cell><cell></cell><cell>Adjusted</cell><cell>13 (−68-55)</cell><cell>39 (−40-73)</cell><cell>41 (12-61)</cell></row><row><cell>VE, vaccine effectiveness.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">§ VE point estimates were rounded off to whole numbers.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">2 approx. VE since data for this age group were presented as figures only.</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">3 VE against all influenza types; &gt;80% of all subtypes identified were H1N1.</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">4 VE against all-type influenza hospitalization; 76% of all subtypes identified were H1N1.</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">5 VE against all-type hospitalization; 95% of all subtypes identified were H1N1.</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">6 VE against all influenza types; 56% of all subtypes identified were H1N1, 41% were B.</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">7 VE against all influenza cases; 92% of all subtypes identified were H3N2.</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">8 Data extracted from the study of Darvishian et al. [31].</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>1 I-9 VE against all influenza types; distribution among the whole study population: 41% H1N1, 40% B, 19% H3N2. 10 VE against all influenza types; distribution among the whole study population: 53% H1N1, 43% B. 11 VE against hospitalization; data collected in Spain, France and in the Russian Federation.</s><s>12 adjusted for study site.</s></p></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>The authors are grateful to all colleagues at local and federal health departments in Germany for the collection and reporting of relevant data.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Additional file</head><p><s>Additional file 1: Table <ref type="table">S1</ref>.</s><s>Sensitivity analysis in which cases (n=9) were excluded who were vaccinated &lt;14 days prior to symptom onset.</s><s>Table <ref type="table">S2</ref>.</s><s>Baseline characteristics of excluded vs. included cases.</s><s>Table <ref type="table">S3</ref>.</s><s>Sensitivity analysis in which vaccination coverage among excluded cases was considered 50% and 200% of vaccination coverage of included cases, respectively.</s><s>Table <ref type="table">S4</ref>.</s><s>Baseline characteristics of cases with exact date of vaccination compared to those without this information.</s><s>Table <ref type="table">S5</ref>.</s><s>Sensitivity analysis in which 50% of cases without information on exact date of vaccination were considered as non-vaccinated.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Competing interests</head><p><s>The authors declare that they have no competing interests.</s></p><p><s>Authors' contributions CR and OW were responsible for the study design.</s><s>CR performed data collection, statistical analysis and interpretation of the data and drafted the manuscript.</s><s>TR and BB performed data collection and statistical analysis.</s><s>TR, BB and OW gave important intellectual content and revised the manuscript critically.</s><s>All authors read and approved the final manuscript.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">D</forename><surname>Mertz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Johnstone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Lam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Science</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Kuster</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">347</biblScope>
			<biblScope unit="page">5061</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices-United States</title>
	</analytic>
	<monogr>
		<title level="j">Centers for Disease Control and Prevention (CDC)</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="1" to="43" />
			<date type="published" when="2013">2013-2014. 2013</date>
		</imprint>
	</monogr>
	<note>MMWR Recomm Rep</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Influenza. The green book</title>
		<ptr target="https://www.gov.uk/government/publications/influenza-the-green-book-chapter" />
	</analytic>
	<monogr>
		<title level="j">Public Health England. Chapter</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<date type="published" when="2013-03-20">11 September 2013. 2013. 20 March 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">German Standing Committee on Vaccination (STIKO)</title>
	</analytic>
	<monogr>
		<title level="m">Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: August</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<ptr target="https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2013/Ausgaben/34_13.pdf" />
	</analytic>
	<monogr>
		<title level="m">;jsessionid= 7DE55B422304CC5842CE18900F8E43A1.2_cid372?__blob=publicationFile. Accessed on</title>
				<imprint>
			<date type="published" when="2013-03-19">2013. 2013. 19 March 2014</date>
			<biblScope unit="volume">34</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">Background Paper on Influenza Vaccines and Immunization</title>
		<ptr target="http://www.who.int/entity/immunization/sage/meetings/2012/april/1_Background_Paper_Mar26_v13_cleaned.pdf?ua=1" />
		<imprint>
			<date type="published" when="2012-03-19">2012. 19 March, 2014</date>
		</imprint>
		<respStmt>
			<orgName>World Health Organization, Strategic Advisory Group of Expertes (SAGE) Working Group</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Council recommendation of 22-12-2009 on seasonal influenza vaccination 2009/1019/EU</title>
		<ptr target="http://www.epha.org/IMG/pdf/Council_Reccomendation_on_seasonal_flu_vaccine.pdf" />
	</analytic>
	<monogr>
		<title level="j">Official Journal of the European Union</title>
		<imprint>
			<date type="published" when="2009-06">29/12/2009. 2009. June 2014</date>
		</imprint>
	</monogr>
	<note>European Union</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Immunosenescence: role and measurement in influenza vaccine response among the elderly</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">V</forename><surname>Targonski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Jacobson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Poland</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="3066" to="3069" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Vaccines for preventing influenza in the elderly</title>
		<author>
			<persName><forename type="first">T</forename><surname>Jefferson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Pietrantonj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Al-Ansary</forename></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Ferroni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Thorning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cochrane Database Syst RevI</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">3</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Osterholm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">S</forename><surname>Kelley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sommer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Belongia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="36" to="44" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Cochrane re-arranged: support for policies to vaccinate elderly people against influenza</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Beyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mcelhaney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Monto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Nguyen-Van-Tam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Osterhaus</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="6030" to="6033" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Editorial commentary: annual studies of influenza vaccine effectiveness: evaluating performance, informing policy, and generating new questions</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Neuzil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Victor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="328" to="329" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Report on the first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Girard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Tam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Pervikov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Katz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="3766" to="3771" />
			<date type="published" when="2013-01">January 2013. 2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Skowronski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">Z</forename><surname>Janjua</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Serres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Winter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Dickinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Gardy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="332" to="342" />
			<date type="published" when="2010">Canada 2010-2011. 2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">I-MOVE: a European network to measure the effectiveness of influenza vaccines</title>
		<author>
			<persName><forename type="first">M</forename><surname>Valenciano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Ciancio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ims</forename><surname>Team</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Euro Surveill</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Treanor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Talbot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Ohmit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Coleman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">Y</forename><surname>Cheng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="951" to="959" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Estimation of type-and subtype-specific influenza vaccine effectiveness in Victoria, Australia using a test negative case control method</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Fielding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Grant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Papadakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Kelly</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Infect Dis</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">170</biblScope>
			<date type="published" when="2007">2007-2008. 2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Effectiveness of trivalent and monovalent influenza vaccines against laboratory-confirmed influenza infection in persons with medically attended influenza-like illness in Bavaria</title>
		<author>
			<persName><forename type="first">H</forename><surname>Englund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Campe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Hautmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Epidemiol Infect</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="page" from="1807" to="1815" />
			<date type="published" when="2010">2010. 2011. 2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials</title>
		<author>
			<persName><forename type="first">De</forename><surname>Serres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Skowronski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">W</forename><surname>Ambrose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Euro Surveill</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">37</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">The test-negative design for estimating influenza vaccine effectiveness</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Jackson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Nelson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="2165" to="2168" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks</title>
		<author>
			<persName><forename type="first">M</forename><surname>Valenciano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kissling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Ciancio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Moren</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="7381" to="7388" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Field seasonal influenza vaccine effectiveness: Evaluation of the screening method using different sources of data during the 2010/2011 French influenza season</title>
		<author>
			<persName><forename type="first">A</forename><surname>Falchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Souty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Grisoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mosnier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hanslik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Daviaud</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Vaccin Immunother</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="2453" to="2459" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Estimating vaccine effectiveness against severe influenza in England and Scotland 2011/2012: applying the screening method to data from intensive care surveillance systems</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Andrews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>Boddington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Reynolds</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Epidemiol Infect</title>
		<imprint>
			<biblScope unit="volume">142</biblScope>
			<biblScope unit="page" from="126" to="133" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">screening method working g. Estimating pandemic vaccine effectiveness in two Italian regions using the screening method</title>
		<author>
			<persName><forename type="first">T</forename><surname>Seyler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Puzelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Donatelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rizzo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="109" to="111" />
			<date type="published" when="2009">2009-2010. 2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany</title>
		<author>
			<persName><forename type="first">O</forename><surname>Wichmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Stocker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Poggensee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Altmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Walter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Hellenbrand</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Euro Surveill</title>
		<imprint>
			<biblScope unit="page">15</biblScope>
			<date type="published" when="2009">2009-2010. 2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Estimation of vaccine effectiveness using the screening method</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Farrington</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="742" to="746" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Influenza vaccine effectiveness: best practice and current limitations of the screening method and their implications for the clinic</title>
		<author>
			<persName><forename type="first">L</forename><surname>Minodier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Blanchon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Souty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Turbelin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Leccia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Varesi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Rev Vaccines</title>
		<imprint>
			<biblScope unit="page" from="1" to="10" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Vaccination coverage among children in Germany estimated by analysis of health insurance claims data</title>
		<author>
			<persName><forename type="first">T</forename><surname>Rieck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Feig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Eckmanns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Benzler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Siedler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Wichmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Vaccin Immunother</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="476" to="484" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">SurvNet electronic surveillance system for infectious disease outbreaks</title>
		<author>
			<persName><forename type="first">G</forename><surname>Krause</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Altmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Faensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Porten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Benzler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pfoch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Germany. Emerg Infect Dis</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1548" to="1555" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<monogr>
		<title level="m" type="main">Bericht zur Epidemiologie der Influenza in Deutschland Saison</title>
		<ptr target="https://influenza.rki.de/Saisonberichte/2012.pdf" />
		<editor>Robert Koch-Institut (RKI</editor>
		<imprint>
			<date type="published" when="2012">2012. 2013</date>
			<biblScope unit="volume">13</biblScope>
		</imprint>
	</monogr>
	<note>Berlin: RKI</note>
</biblStruct>

<biblStruct xml:id="b30">
	<monogr>
		<title level="m" type="main">Bericht zur Epidemiologie der Influenza in Deutschland Saison</title>
		<ptr target="https://influenza.rki.de/Saisonberichte/2010.pdf" />
		<editor>Robert Koch-Institut (RKI</editor>
		<imprint>
			<date type="published" when="2010">2010. 2011</date>
		</imprint>
	</monogr>
	<note>Berlin: RKI</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a metaanalysis of test-negative design case-control studies</title>
		<author>
			<persName><forename type="first">M</forename><surname>Darvishian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Bijlsma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Van Den Heuvel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="1228" to="1239" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies</title>
		<author>
			<persName><forename type="first">E</forename><surname>Von Elm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Egger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Pocock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Gotzsche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Vandenbroucke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="344" to="349" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Estimates of 2012/13 influenza vaccine effectiveness using the case test-negative control design with different influenza negative control groups</title>
		<author>
			<persName><forename type="first">B</forename><surname>Nunes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Machado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Guiomar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Pechirra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Conde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Cristovao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="4443" to="4449" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Seasonal Influenza Vaccine Effectiveness against Influenza Hospitalizations: Results from the Global Influenza Hospital Surveillance Network</title>
		<author>
			<persName><forename type="first">J</forename><surname>Puig-Barbera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Natividad-Sancho</forename></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Launay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Burtseva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ciblak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Tormos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">e100497</biblScope>
			<date type="published" when="2012">2012-2013. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Low vaccine effectiveness against influenza A(H3N2) virus among elderly people in Denmark in 2012/13-a rapid epidemiological and virological assessment</title>
		<author>
			<persName><forename type="first">K</forename><surname>Bragstad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Emborg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Voldstedlund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gubbels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Andersen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Euro Surveill</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Early estimates of influenza vaccine effectiveness in Navarre</title>
		<author>
			<persName><forename type="first">J</forename><surname>Castilla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Martinez-Baz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Martinez-Artola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fernandez-Alonso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Reina</forename><forename type="middle">G</forename><surname>Guevara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<idno>Spain: 2012/13</idno>
	</analytic>
	<monogr>
		<title level="j">Euro Surveill</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">2</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>mid-season analysis</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13</title>
		<author>
			<persName><forename type="first">E</forename><surname>Kissling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Valenciano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Buchholz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Larrauri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Nunes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Euro Surveill</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">6</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe</title>
		<author>
			<persName><forename type="first">E</forename><surname>Kissling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Valenciano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Oroszi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Barret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rizzo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">e27622</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study</title>
		<author>
			<persName><forename type="first">E</forename><surname>Kissling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Valenciano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Larrauri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Oroszi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Nunes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Euro Surveill</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">5</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">a population-based test-negative case-control study</title>
		<author>
			<persName><forename type="first">I</forename><surname>Martinez-Baz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Martinez-Artola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Reina</forename><forename type="middle">G</forename><surname>Guevara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cenoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Moran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Public Health</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">191</biblScope>
			<date type="published" when="2010">2010-2011. 2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection</title>
		<author>
			<persName><forename type="first">R</forename><surname>Pebody</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Andrews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mcmenamin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Durnall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ellis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">I</forename><surname>Thompson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Euro Surveill</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">5</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Pebody</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Andrews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Fleming</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mcmenamin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cottrell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Smyth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Epidemiol Infect</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="620" to="630" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Effectiveness of the 2010-2011 seasonal influenza vaccine in preventing confirmed influenza hospitalizations in adults: a case-case comparison, case-control study</title>
		<author>
			<persName><forename type="first">J</forename><surname>Puig-Barbera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Diez-Domingo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Arnedo-Pena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ruiz-Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Perez-Vilar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Mico-Esparza</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="5714" to="5720" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results</title>
		<author>
			<persName><forename type="first">N</forename><surname>Andrews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mcmenamin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Durnall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ellis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lackenby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Robertson</surname></persName>
		</author>
		<ptr target="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20851" />
	</analytic>
	<monogr>
		<title level="j">Euro Surveill</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">27</biblScope>
			<biblScope unit="page">12</biblScope>
			<date type="published" when="2014-07">2014. July 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Vaccine effectiveness in preventing influenza hospitalizations in Navarre</title>
		<author>
			<persName><forename type="first">J</forename><surname>Castilla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Martinez-Artola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Salcedo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Martinez-Baz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Cenoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Guevara</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="195" to="200" />
			<date type="published" when="2010">Spain, 2010-2011. 2012</date>
		</imprint>
	</monogr>
	<note>: cohort and case-control study</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Effectiveness of the 2010-11 seasonal trivalent influenza vaccine in Spain: cycEVA study</title>
		<author>
			<persName><forename type="first">S</forename><surname>Jimenez-Jorge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Savulescu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Pozo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>De Mateo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Casas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ledesma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="3595" to="3602" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population targeted for vaccination</title>
		<author>
			<persName><forename type="first">S</forename><surname>Jimenez-Jorge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>De Mateo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Delgado-Sanz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Pozo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Casas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Garcia-Cenoz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Infect Dis</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">441</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Seasonal influenza vaccine effectiveness against influenza in 2012-2013: a hospital-based case-control study in Lithuania</title>
		<author>
			<persName><forename type="first">G</forename><surname>Gefenaite</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rahamat-Langendoen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ambrozaitis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mickiene</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Jancoriene</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kuliese</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="857" to="863" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Decline in influenza vaccine effectiveness with time after vaccination</title>
		<author>
			<persName><forename type="first">J</forename><surname>Castilla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Martinez-Baz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Martinez-Artola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Reina</forename><forename type="middle">G</forename><surname>Pozo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Garcia</forename><surname>Cenoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Euro Surveill</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">5</biblScope>
			<date type="published" when="2011">2011/12. 2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">I-MOVE&quot; towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in Europe</title>
		<author>
			<persName><forename type="first">E</forename><surname>Kissling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Valenciano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Falcao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Larrauri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Widgren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Pitigoi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Euro Surveill</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">44</biblScope>
			<biblScope unit="page" from="2008" to="2009" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">The case test-negative design for studies of the effectiveness of influenza vaccine</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Foppa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Haber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Ferdinands</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Shay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="3104" to="3109" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Assessing vaccine efficacy in the field</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Orenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Bernier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Hinman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Further observations Epidemiol Rev</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="212" to="241" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">seasons: a secondary data analysis based on billing data of the German associations of statutory health insurance physicians</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Reuss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Walter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Feig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kappelmayer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Buchholz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Eckmanns</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dtsch Arztebl Int</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="845" to="850" />
			<date type="published" when="2004">2004/05, 2005/06, and 2006/07. 2010</date>
		</imprint>
	</monogr>
	<note>Influenza vaccination coverage in the</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Influenza A/subtype and B/lineage effectiveness estimates for the 2011-12 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Skowronski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">Z</forename><surname>Janjua</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sabaiduc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Serres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Winter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Gubbay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">210</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="126" to="137" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<monogr>
		<title level="m" type="main">Recommended composition of influenza virus vaccines for use in the 2013-14 northern hemisphere influenza season</title>
		<ptr target="http://www.who.int/influenza/vaccines/virus/recommendations/2013_14_north/en/.Accessedon10" />
		<imprint>
			<date type="published" when="2013-07">2013. July 2014</date>
		</imprint>
	</monogr>
	<note>World Health Organization</note>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Comparison of the mutation rates of human influenza A and B viruses</title>
		<author>
			<persName><forename type="first">E</forename><surname>Nobusawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sato</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Virol</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="page" from="3675" to="3678" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Influenza vaccine effectiveness in preventing outpatient, inpatient, and severe cases of laboratory-confirmed influenza</title>
		<author>
			<persName><forename type="first">J</forename><surname>Castilla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Godoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dominguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Martinez-Baz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Astray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Martin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="167" to="175" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
